Safety Reading Notes

Read safety context beside the research guide.

The CBCA source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 36257598

PubMed For Dummies Article

CBCA Evidence Review: the long-form source walk-through

Quick read
  • CBCA currently has 23 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 36257598
  • The evidence classes most visible in the row language are insufficient (16), mechanistic or pharmacological (5), preclinical (1), and preliminary human (1). PMID 41545891
  • The study-design language most visible in the row language is Narrative or expert review (5), Cellular or in vitro study (5), Animal study (4), and other mapped categories (1). PMID 41822224
  • The repeated topics are receptor, target, or pharmacology mechanisms (12), receptor, transporter, target, metabolic, or pharmacology mechanisms (4), neurobehavioral, mood, neural stem cell, or neurogenesis outcomes (2), Pain-related outcomes (1), and other mapped categories (4), which tells the reader where to start opening PubMed and DOI links. PMID 37083031

Start with the research question

CBCA is built from 23 source-backed evidence row(s) and 17 research source(s). The current evidence classes read as insufficient (16), mechanistic or pharmacological (5), preclinical (1), and preliminary human (1), and the study-design language most often reads as Narrative or expert review (5), Cellular or in vitro study (5), Animal study (4), and other mapped categories (1). PMID 36257598

The row-level question is not simply whether CBCA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (12), receptor, transporter, target, metabolic, or pharmacology mechanisms (4), neurobehavioral, mood, neural stem cell, or neurogenesis outcomes (2), Pain-related outcomes (1), and other mapped categories (4). PMID 40006604

Human evidence 1 row

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 38162115

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 34980287

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 34384142

Limits and uncertainty 17 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 40006604

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 32824356

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, transporter, target, metabolic, or pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 36257598

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 40006604

Bucket chapters: what the literature is circling

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (201-287) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

CBCA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36257598

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36257598

  • Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

  • Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

receptor, transporter, target, metabolic, or pharmacology mechanisms

4 research sources 4 rows (661-677) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)

CBCA appears in rows about receptor, transporter, target, metabolic, or pharmacology mechanisms mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40006604

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40006604

  • Evidence row 661

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacol... PMID 40006604

  • Evidence row 677

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37023389

receptor, target, or pharmacology mechanisms

3 research sources 3 rows (279-281) Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)

CBCA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34980287

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34980287

  • Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharma... PMID 34980287

  • Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

2 research sources 2 rows (722-723) Mapped evidence with interpretation limits: insufficient (2)

CBCA appears in rows studying neurobehavioral, mood, neural stem cell, or neurogenesis outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39808700

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39808700

  • Evidence row 722

    CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 39808700

  • Evidence row 723

    CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measu... PMID 35306000

receptor, target, or pharmacology mechanisms

2 research sources 2 rows (283-284) Mapped evidence with interpretation limits: insufficient (2)

CBCA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39808700

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39808700

  • Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

  • Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target,... PMID 35306000

Inflammation-related outcomes

1 research source 71 Mapped evidence with interpretation limits: insufficient (1)

CBCA appears in rows studying Inflammation-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41545891

  • Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammatio... PMID 41545891

nausea-related or inflammation-related outcomes

1 research source 125 Mapped evidence with interpretation limits: insufficient (1)

CBCA appears in rows studying nausea-related or inflammation-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41545891

  • Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome m... PMID 41545891

Pain-related outcomes

1 research source 70 Mapped evidence with interpretation limits: insufficient (1)

CBCA appears in rows studying Pain-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41545891

  • Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcom... PMID 41545891

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (1 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (1 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 36257598

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 40006604

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 39808700
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 35306000
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 37708768

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 36257598

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 40006604

Source-reading checklist for CBCA

  1. Open the linked PubMed or DOI record. PMID 39013926
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35566314
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 33395525
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 37023389
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 41983582

Source Notes

CBCA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  2. Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  3. Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  4. Evidence row 165

    CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41822224

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.
  5. Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

    Evidence class: insufficient. Source: Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.
  6. Evidence row 277

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 37083031

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
  7. Evidence row 278

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 38162115

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.
  8. Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34980287

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.
  9. Evidence row 280

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142

    Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
  10. Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  11. Evidence row 282

    CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 32824356

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.
  12. Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

    Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
  13. Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  14. Evidence row 285

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 37708768

    Evidence class: insufficient. Source: Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.
  15. Evidence row 286

    THCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39013926

    Evidence class: insufficient. Source: Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.
  16. Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

    Evidence class: insufficient. Source: Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.
  17. Evidence row 661

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  18. Evidence row 662

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35306000

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  19. Evidence row 673

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 33395525

    Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.
  20. Evidence row 677

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37023389

    Evidence class: insufficient. Source: Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains.
  21. Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41983582

    Evidence class: preliminary human. Source: Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.
  22. Evidence row 722

    CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 39808700

    Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
  23. Evidence row 723

    CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.